Mirtazapine, an
Adrenergic alpha-2 Receptor Antagonists
/ administration & dosage
Animals
Antidepressive Agents
/ administration & dosage
Chronic Pain
/ drug therapy
Disease Models, Animal
Fibromyalgia
/ drug therapy
Gene Expression Regulation
/ drug effects
Hyperalgesia
/ prevention & control
Injections, Intraventricular
Injections, Spinal
Male
Mice
Mice, Inbred C57BL
Mirtazapine
/ administration & dosage
Morphine
/ administration & dosage
Pain Measurement
Receptors, Adrenergic, alpha-2
/ genetics
Journal
The Journal of pharmacology and experimental therapeutics
ISSN: 1521-0103
Titre abrégé: J Pharmacol Exp Ther
Pays: United States
ID NLM: 0376362
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
25
02
2020
accepted:
13
07
2020
pubmed:
16
7
2020
medline:
15
12
2020
entrez:
16
7
2020
Statut:
ppublish
Résumé
Treatment of fibromyalgia is an unmet medical need; however, its pathogenesis is still poorly understood. In a series of studies, we have demonstrated that some pharmacological treatments reverse generalized chronic pain but do not affect the lack of morphine analgesia in the intermittent cold stress (ICS)-induced fibromyalgia-like pain model in mice. Here we report that repeated intraperitoneal treatments with mirtazapine, which is presumed to disinhibit 5-hydroxytriptamine (5-HT) release and activate 5-HT1 receptor through mechanisms of blocking presynaptic adrenergic
Identifiants
pubmed: 32665319
pii: jpet.120.265942
doi: 10.1124/jpet.120.265942
doi:
Substances chimiques
Adrenergic alpha-2 Receptor Antagonists
0
Antidepressive Agents
0
Receptors, Adrenergic, alpha-2
0
Morphine
76I7G6D29C
Mirtazapine
A051Q2099Q
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-9Informations de copyright
Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.